![discount label](https://static.cymitquimica.com/public/img/discount.png)
Información del producto
- 1-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
- N-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N′-methoxyurea
- Orgovyx
- Rvt 601
- TAK-385,Relugolix
- Tak-385
- Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N′-methoxy-
Relugolix is a hormone antagonist that blocks the effects of androgens such as testosterone. It is used to treat prostate cancer, endometriosis, and other conditions. Relugolix has been shown to be an effective treatment for prostate cancer when used in combination with other therapies such as platinum-based chemotherapy or radiation therapy. Relugolix has been shown to block not only the effects of testosterone but also other hormones like estrogens and progesterone, which may be beneficial in treating endometriosis. Relugolix has also been shown to inhibit urothelial carcinoma cells.
Propiedades químicas
Consulta técnica sobre: 3D-MEB78987 Relugolix
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.